Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.
Guru P. Sonpavde, MD, director, the Bladder Cancer Program, Dana-Farber Cancer Institute, faculty, Harvard Medical School, discusses the investigation of enfortumab vedotin-ejfv (Padcev) with or without pembrolizumab (Keytruda) in urothelial cancer.
The phase 1/2 EV-103 trial (NCT03288545) is investigating the use of enfortumab vedotin alone or in combination with pembrolizumab in patients with advanced or metastatic urothelial cancer.
The combination of enfortumab vedotin plus pembrolizumab has demonstrated antitumor activity in the first-line setting for patients who are ineligible for cisplatin-based chemotherapy, Sonpavde says. Data from cohort K presented at the 2022 ESMO Congress showed that the combination elicited a confirmed overall response rate of 64.5%, which was similar to previously reported data from the dose-escalation portion of the trial.
These findings added to the belief that enfortumab vedotin plus pembrolizumab can potentially be practice changing, Sonpavde explains. If this regimen receives approval, clinicians will need to decide between platinum-based chemotherapy followed by maintenance avelumab (Bavencio) or the combination of enfortumab vedotin plus pembrolizumab, Sonpavde concludes.